Overview

Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes

Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
0
Participant gender:
All
Summary
To investigate the Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes,100 patients with T2DM will be enrolled in this study.They will randomly be assigned to Acarbose+Saxagliptin or Metformin+Saxagliptin group.HbA1c,fasting and postprandial C-peptide will be observed before and after the interventions.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fifth Affiliated Hospital, Sun Yat-Sen University
Treatments:
Acarbose
Metformin
Saxagliptin
Criteria
Inclusion Criteria:

- Newly diagnosed type 2 diabetes mellitus(course of disease less than one year) who has
not receive drug treatment.

- T2DM patients who has not receive drug treatment for three months at least.

- HbA1c for 7.5-10%.

Exclusion Criteria:

- New or worsening signs or symptoms of coronary heart disease

- Medical history of active liver disease and kidney disease

- Poorly controlled hypertension(systolic blood pressure>160mmHg or diastolic blood
pressure>95mmHg)

- A clinically important hematological disorder

- A history of intolerance or hypersensitivity or any contraindication to study
medications (including saxagliptin, metformin, acarbose)

- Is pregnant or breast feeding or is expecting to conceive or donate eggs

- A medical history of drug abuse

- Can not be followed -up on time

- Endocrinological diseases(eg: hyperthyroidism、hypothyroidisn and cushing syndrom)

- Gastrointestinal diseases

- Mental disorser

- Hypoxic disease